iBio’s FastPharming Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2ACE2 (angiotensin-converting enzyme-2), Business, Immunoadhesin Molecules, Licensing, Product Pipeline, R&D, Recombinant Proteins, SARS-CoV-2 spike protein, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), TherapeuticsiBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2. Read more September 16, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/09/iBio’s-FastPharming®-Platform-Produces-Decoy-Therapeutic-to-Bind-to-SARS-CoV-2-BioSpace-9-16-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-09-16 11:59:532020-09-16 12:41:33iBio’s FastPharming Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2
